New therapeutic strategies for lung cancer: Biology and molecular biology come of age

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 163S-168S

  Bunn Jr , Paul A ^a   Soriano, Ariel ^a   Johnson, Gary ^a   Heasley, Lynn ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; Growth factor; Lung cancer; Oncogene; Receptors; Suppressor gene

Indexed keywords

AG 33340; BATIMASTAT; BRADYKININ ANTAGONIST; BRYOSTATIN; MARIMASTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C INHIBITOR; SUBSTANCE P DERIVATIVE; TANOMASTAT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; CLINICAL TRIAL; CONFERENCE PAPER; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOLECULAR BIOLOGY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0343238257     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Kane M, Bunn PA Jr. Biology of lung cancer. (vol 122). New York, NY: Marcel Dekker, 1998
2. Sporn MB, Todaro GJ. Autocrine growth factors and cancer. Nature 1985; 313:747-751
3. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44:1002-1007
4. Cerny T, Barnes DM, Hasleton PS, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Br J Cancer 1986; 54:265-269
5. Rusch V, Klimstra D, Linkov I, et al. Aberrant expression of p53 and the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995; 55: 1365-1372
6. Bos M, Mendelsohn J, Bowden D, et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors [abstract 1381]. Proc Am Soc Clin Oncol 1996; 15:443
7. 389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 1991; 51:2118-2124
8. Bos M, Mendelsohn J, Kim YM, et al. PD 153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 1997; 3:2099-2106
9. Vollman AM, Banker DE, Mendelsohn J, et al. Toxicity of ligand and antibody-directed ricin A chain conjugates recognizing the epidermal growth factor receptor. J Cell Physiol 1987; 131:418-425
10. Sherwin SA, Minna JD, Gazdar AF, et al. Expression of epidermal and nerve growth factor receptors and soft aganose growth factor production by human lung cancer cells. Cancer Res 1981; 41:3538-3542
11. Fontanini G, DeLaurentis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241-249
12. Nakanishi Y, Mulshine J, Kasprzyk PG, et al. Insulin like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 1988; 82:354-359
13. Bunn PA Jr, Dienhard DG, Chan D, et al. Neuropeptide stimulation of calcium flux in human lung cancer cells: delineation of alternative pathways. Proc Natl Acad Sci USA USA 1990; 87:2162-2166
14. Bunn PA Jr, Chan D, Stewart J, et al. Effects of neuropeptides analogs on calcium flux and proliferation in lung cancer cell lines. Cancer Res 1994; 54:3602-3610
15. Woll PJ, Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 1988; 48:4783-4789
16. 11] Substance P inhibits the growth of human small cell lung cancer xenografts in vivo. Eur J Cancer 1993; 29A:1450-1453
17. 11] substance P. J Biol Chem 1995; 270:8623-8628
18. Dhanasekaran N, Heasley LE, Johnsen GL. G-protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr Rev 1995; 16:259-270
19. Mukai H, Munekata E, Higashijima T. G-protein antagonists. J Biol Chem 1992; 267:16237-16243
20. Heasley LE, Zamarripa J, Storey B, et al. Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase deficient Gal6. J Biol Chem 1996; 271:349-356
21. Sano H, Kawakito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-3789
22. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res 1995; 55:1464-1472
23. Thompson HJ, Briggs S, Paranka N, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995; 87:1259-1260
24. Soriano A, Chan D, Helfrich B, et al. Non-steroidal anti-inflammatory drugs (NSAIDS) inhibit the in vitro and in vivo growth of human lung cancer. Proc Am Assoc Cancer Res 1998; 39:1336
25. Piazza G, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57:2452-2459
26. Piazza GA, Kulchak-Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulindac sulfane inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55:3110-3116
27. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastases. J Natl Cancer Inst 1997; 89:1260-1270
28. Sledge GWJ, Qulali M, Gailet R, et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastases in athymic mice. J Natl Cancer Inst 1995; 87:1546-1550
29. Davies B, Brown PO, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53:2087-2091
30. Moses MA, Langer RA. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Physiol 1991; 47:230-235
31. Folkman J. Clinical application of research on angiogenesis. N Engl J Med 1995; 333:1757-1763
32. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-4599
33. O'Reilly MS, Goehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285
34. Levesque L, Dean NM, Sasmor H, et al. Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbolester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol Pharmacol 1997; 51: 209-216
35. Grant S, Jarvis WD. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 1996; 2:1915-1920
36. Prendiville J, Crowther D, Thatcher N, et al. A phase I study of intravenous bryostatin I in patients with advanced cancer. Br J Cancer 1993; 68:418-424
37. Johnson BE, Kelley MJ. Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest 1993; 103:15-35
38. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53:4029-4123
39. Roth JA, Nguyen P, Lawrence DD, et al. Retroviral-mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-991
40. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54:2287-2291
41. Tursz T, de Cisne A, Baldeyrou P, et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996; 88:1857-1863
42. Schauer IE, Siriwardana S, Langan TA, et al. Cyclin D1 overexpression vs retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA USA 1994; 91:7827-7831
43. Kelly MJ, Nakagawa K, Steinberg SM, et al. Differentiated inactivation of CDKN2 and Rb proteins in non-small cell and small cell lung cancer cell lines. J Natl Cancer Inst 1995; 87:756-761
44. Ookawa K, Shiseki M, Takahashi R, et al. Reconstitution of the Rb gene suppresses the growth of small cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 1993; 8:2175-2182
45. INK4 gene mediated by an adenovirus vector. Cancer Res 1995; 55: 3250-3253
46. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1991; 323:1353-1362
47. Mukhopadhyay T, Tainsky M, Cavander AC, et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 1991; 51:1744-1748
48. Kern JA, Schwartz DA, Nordberg JE, et al. p185 neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50:5184-5191
49. Kakeya H, Onose R, Lui PCC, et al. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine a nucleotide antibiotic. Cancer Res 1998; 58:704-710
50. Robinson LA, Smith LJ, Fontaine MP, et al. C-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer. Ann Thorac Surg 1995; 60:1583-1591
51. Gibbs JB, Oliff A, Kohl NE. Farnesylation inhibitors: ras research yields a potential cancer therapeutic. Cell 1994; 77:175-178
52. HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744